Cargando…

MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes

BACKGROUND: Microsatellite instability (MSI) has emerged as a predictive biomarker for immune checkpoint inhibitor therapy. Cancer heterogeneity represents a potential obstacle for the analysis of predicitive biomarkers. MSI has been reported in pancreatic cancer, but data on the possible extent of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraune, Christoph, Burandt, Eike, Simon, Ronald, Hube-Magg, Claudia, Makrypidi-Fraune, Georgia, Kluth, Martina, Büscheck, Franziska, Höflmayer, Doris, Blessin, Niclas Ch., Mandelkow, Tim, Li, Wenchao, Perez, Daniel, Izbicki, Jakob R., Wilczak, Waldemar, Sauter, Guido, Schrader, Jörg, Neipp, Michael, Mofid, Hamid, Daniels, Thies, Isbert, Christoph, Clauditz, Till S., Steurer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471097/
https://www.ncbi.nlm.nih.gov/pubmed/32108923
http://dx.doi.org/10.1245/s10434-020-08209-y
_version_ 1783578711868571648
author Fraune, Christoph
Burandt, Eike
Simon, Ronald
Hube-Magg, Claudia
Makrypidi-Fraune, Georgia
Kluth, Martina
Büscheck, Franziska
Höflmayer, Doris
Blessin, Niclas Ch.
Mandelkow, Tim
Li, Wenchao
Perez, Daniel
Izbicki, Jakob R.
Wilczak, Waldemar
Sauter, Guido
Schrader, Jörg
Neipp, Michael
Mofid, Hamid
Daniels, Thies
Isbert, Christoph
Clauditz, Till S.
Steurer, Stefan
author_facet Fraune, Christoph
Burandt, Eike
Simon, Ronald
Hube-Magg, Claudia
Makrypidi-Fraune, Georgia
Kluth, Martina
Büscheck, Franziska
Höflmayer, Doris
Blessin, Niclas Ch.
Mandelkow, Tim
Li, Wenchao
Perez, Daniel
Izbicki, Jakob R.
Wilczak, Waldemar
Sauter, Guido
Schrader, Jörg
Neipp, Michael
Mofid, Hamid
Daniels, Thies
Isbert, Christoph
Clauditz, Till S.
Steurer, Stefan
author_sort Fraune, Christoph
collection PubMed
description BACKGROUND: Microsatellite instability (MSI) has emerged as a predictive biomarker for immune checkpoint inhibitor therapy. Cancer heterogeneity represents a potential obstacle for the analysis of predicitive biomarkers. MSI has been reported in pancreatic cancer, but data on the possible extent of intratumoral heterogeneity are lacking. METHODS: To study MSI heterogeneity in pancreatic cancer, a tissue microarray (TMA) comprising 597 tumors was screened by immunohistochemistry with antibodies for the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6. RESULTS: In six suspicious cases, large section immunohistochemistry and microsatellite analysis (Bethesda panel) resulted in the identification of 4 (0.8%) validated MSI cases out of 480 interpretable pancreatic ductal adenocarcinomas. MSI was absent in 55 adenocarcinomas of the ampulla of Vater and 7 acinar cell carcinomas. MMR deficiency always involved MSH6 loss, in three cases with additional loss of MSH2 expression. Three cancers were MSI-high and one case with isolated MSH6 loss was MSS in PCR analysis. The analysis of 44 cancer-containing tumor blocks revealed that the loss of MMR protein expression was always homogeneous in affected tumors. Automated digital image analysis of CD8 immunostaining demonstrated markedly higher CD8 + tumor infiltrating lymphocytes in tumors with (mean = 685, median = 626) than without (mean = 227; median = 124) MMR deficiency (p < 0.0001), suggesting a role of MSI for immune response. CONCLUSIONS: Our data suggest that MSI occurs early in a small subset of ductal adenocarcinomas of the pancreas and that immunohistochemical MMR analysis on limited biopsy or cytology material may be sufficient to estimate MMR status of the entire cancer mass. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-020-08209-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7471097
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74710972020-09-16 MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes Fraune, Christoph Burandt, Eike Simon, Ronald Hube-Magg, Claudia Makrypidi-Fraune, Georgia Kluth, Martina Büscheck, Franziska Höflmayer, Doris Blessin, Niclas Ch. Mandelkow, Tim Li, Wenchao Perez, Daniel Izbicki, Jakob R. Wilczak, Waldemar Sauter, Guido Schrader, Jörg Neipp, Michael Mofid, Hamid Daniels, Thies Isbert, Christoph Clauditz, Till S. Steurer, Stefan Ann Surg Oncol Translational Research and Biomarkers BACKGROUND: Microsatellite instability (MSI) has emerged as a predictive biomarker for immune checkpoint inhibitor therapy. Cancer heterogeneity represents a potential obstacle for the analysis of predicitive biomarkers. MSI has been reported in pancreatic cancer, but data on the possible extent of intratumoral heterogeneity are lacking. METHODS: To study MSI heterogeneity in pancreatic cancer, a tissue microarray (TMA) comprising 597 tumors was screened by immunohistochemistry with antibodies for the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6. RESULTS: In six suspicious cases, large section immunohistochemistry and microsatellite analysis (Bethesda panel) resulted in the identification of 4 (0.8%) validated MSI cases out of 480 interpretable pancreatic ductal adenocarcinomas. MSI was absent in 55 adenocarcinomas of the ampulla of Vater and 7 acinar cell carcinomas. MMR deficiency always involved MSH6 loss, in three cases with additional loss of MSH2 expression. Three cancers were MSI-high and one case with isolated MSH6 loss was MSS in PCR analysis. The analysis of 44 cancer-containing tumor blocks revealed that the loss of MMR protein expression was always homogeneous in affected tumors. Automated digital image analysis of CD8 immunostaining demonstrated markedly higher CD8 + tumor infiltrating lymphocytes in tumors with (mean = 685, median = 626) than without (mean = 227; median = 124) MMR deficiency (p < 0.0001), suggesting a role of MSI for immune response. CONCLUSIONS: Our data suggest that MSI occurs early in a small subset of ductal adenocarcinomas of the pancreas and that immunohistochemical MMR analysis on limited biopsy or cytology material may be sufficient to estimate MMR status of the entire cancer mass. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-020-08209-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-02-27 2020 /pmc/articles/PMC7471097/ /pubmed/32108923 http://dx.doi.org/10.1245/s10434-020-08209-y Text en © The Author(s) 2020, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Translational Research and Biomarkers
Fraune, Christoph
Burandt, Eike
Simon, Ronald
Hube-Magg, Claudia
Makrypidi-Fraune, Georgia
Kluth, Martina
Büscheck, Franziska
Höflmayer, Doris
Blessin, Niclas Ch.
Mandelkow, Tim
Li, Wenchao
Perez, Daniel
Izbicki, Jakob R.
Wilczak, Waldemar
Sauter, Guido
Schrader, Jörg
Neipp, Michael
Mofid, Hamid
Daniels, Thies
Isbert, Christoph
Clauditz, Till S.
Steurer, Stefan
MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
title MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
title_full MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
title_fullStr MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
title_full_unstemmed MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
title_short MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
title_sort mmr deficiency is homogeneous in pancreatic carcinoma and associated with high density of cd8-positive lymphocytes
topic Translational Research and Biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471097/
https://www.ncbi.nlm.nih.gov/pubmed/32108923
http://dx.doi.org/10.1245/s10434-020-08209-y
work_keys_str_mv AT fraunechristoph mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT burandteike mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT simonronald mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT hubemaggclaudia mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT makrypidifraunegeorgia mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT kluthmartina mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT buscheckfranziska mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT hoflmayerdoris mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT blessinniclasch mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT mandelkowtim mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT liwenchao mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT perezdaniel mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT izbickijakobr mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT wilczakwaldemar mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT sauterguido mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT schraderjorg mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT neippmichael mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT mofidhamid mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT danielsthies mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT isbertchristoph mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT clauditztills mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes
AT steurerstefan mmrdeficiencyishomogeneousinpancreaticcarcinomaandassociatedwithhighdensityofcd8positivelymphocytes